IGC Pharma, Inc. (IGC) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Potomac, MD, アメリカ. 現CEOは Ram Mukunda.
IGC を有する IPO日 2006-05-24, 67 名の正社員, に上場 NYSE, 時価総額 $30.64M.
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
